RT Journal Article
SR Electronic
T1 Seroprevalence of Hospital Staff in Province with Zero COVID-19 Cases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20151944
DO 10.1101/2020.07.13.20151944
A1 Nopsopon, Tanawin
A1 Pongpirul, Krit
A1 Chotirosniramit, Korn
A1 Jakaew, Wutichai
A1 Kaewwijit, Chuenkhwan
A1 Kanchana, Sawan
A1 Hiransuthikul, Narin
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.13.20151944.abstract
AB BACKGROUND COVID-19 seroprevalence data has been scarce, especially in less developed countries with a relatively low infection rate.METHODS A locally developed rapid immunoglobulin M (IgM) / immunoglobulin G (IgG) test kit was used for screening hospital staff in Ranong hospital which located in a province with zero COVID-19 prevalence in Thailand from April 17 to May 17, 2020. A total of 844 participants were tested; 82 of which were tested twice with one month apart. (Thai Clinical Trials Registry: TCTR20200426002)RESULTS Overall, 0.8% of the participants (7 of 844) had positive IgM, none had positive IgG. Female staff seemed to have higher IgM seropositive than male staff (1.0% vs. 0.5%). None of the participants with a history of travel to the high-risk area or a history of close contact with PCR-confirmed COVID-19 case had developed antibodies against SARS-CoV-2. Among 844 staff, 811 had no symptom and six of them developed IgM seropositive (0.7%) while 33 had minor symptoms and only one of them developed IgM seropositive (3.0%). No association between IgM antibody against SARS-CoV-2 status and gender, history of travel to a high-risk area, history of close contact with PCR-confirmed COVID-19 case, history of close contact with suspected COVID-19 case, presence of symptoms within 14 days, or previous PCR status was found. None of the hospital staff developed IgG against SARS-CoV-2.CONCLUSION COVID-19 antibody test could detect a substantial number of hospital staffs who could be potential silent spreaders in a province with zero COVID-19 cases. Antibody testing should be encouraged for mass screening, especially in asymptomatic healthcare workers.TRIAL REGISTRATION This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and the Institutional Review Board of Ranong Hospital. (Thai Clinical Trials Registry: TCTR20200426002)FUNDING None.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Clinical Trials Registry: TCTR20200426002Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and the Institutional Review Board of Ranong Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the corresponding author upon request.